Role of the mesenchymal stromal cells in bone marrow failure of Fanconi Anemia patients Provisionally Accepted
- 1Niño Jesús University Children's Hospital, Spain
- 2Fundación para la Investigación del Hospital Niño Jesús, Spain
Introduction: Fanconi anemia (FA) is an inherited disorder characterized by bone marrow failure, congenital malformations, and predisposition to malignancies. Alterations in hematopoietic stem cells (HSC) have been reported, but little is known regarding the bone marrow (BM) stroma. Thus, the characterization of Mesenchymal Stromal Cells (MSC) would help to elucidate their involvement in the BM failure. Methods: We characterized MSCs of 28 FA patients (FA-MSC) before and after treatment (hematopoietic stem cell transplantation, HSCT; or gene therapy, GT). Phenotypic and functional properties were analyzed and compared with MSCs expanded from 26 healthy donors (HD-MSCs). FA-MSCs were genetically characterized through, mitomycin C-test and chimerism analysis. Furthermore, RNA-seq profiling was used to identify dysregulated metabolic pathways. Results: Overall, FA-MSC had the same phenotypic and functional characteristics as HD-MSC. Of note, MSC-GT had a lower clonogenic efficiency. These findings were not confirmed in the whole FA patients' cohort. Transcriptomic profiling identified dysregulation in HSC self-maintenance pathways in FA-MSC (HOX), and was confirmed by real-time quantitative polymerase chain reaction (RT-qPCR). Discussion: Our study provides a comprehensive characterization of FA-MSCs, including for the first time MSC-GT and constitutes the largest series published to date. Interestingly, transcript profiling revealed dysregulation of metabolic pathways related to HSC self-maintenance. Taken together, our results or findings provide new insights into the pathophysiology of the disease, although whether these niche defects are involved in the hematopoietic defects seen of FA deserves further investigation.
Keywords: Mesenchymal stromal cells1, bone marrow microenvironment2, bone marrow failure3, gene therapy4, Fanconi Anemia5
Received: 31 Aug 2023;
Accepted: 13 May 2024.
Copyright: © 2024 Zubicaray, Ivanova, Garcia, Muñoz-Briana, Abad, Iriondo, Garcia, Gonzalez de Pablo, Galvez, Sebastián, Ramirez, Madero, Diaz, Gonzalez Murillo and SEVILLA NAVARRO. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mx. Josune Zubicaray, Niño Jesús University Children's Hospital, Madrid, Spain